- Aging with Grace
The Nun Study and the Science of Old Age
Resource Type: Book
- Alzheimer’s Weekly names ANAVEX 2-73 the number one most promising trial drug in Alzheimer’s disease and Anavex’s Phase I clinical program as “Trial o
Sources News Release
Resource Type: Article/Report/Letter
Published: 2011
ANAVEX 2-73 has been named 2010’s “most promising trial drug” by the editorial staff at Alzheimer’s Weekly.
- ANAVEX 2-73 advances Phase I clinical trial for Alzheimer’s disease
Sources News Release
Resource Type: Article/Report/Letter
Published: 2011
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the firs
- Anavex advances second lead compound; initiates scale-up manufacturing of ANAVEX 1-41
Sources News Release
Resource Type: Article/Report/Letter
Published: 2011
Anavex Life Sciences Corp., (“Anavex”) (OTCBB: AVXL) today announced the initiation of scale-up manufacturing of ANAVEX 1-41, its lead compound for a range of important neurological diseases and a potential back-up compound to ANAVEX 2-73 in Alzheime
- Anavex appoints contract research organizations to initiate Phase I/IIa clinical programs, regulatory strategies in Alzheimer's disease
Sources News Release
Resource Type: Article/Report/Letter
Published: 2010
Anavex Life Sciences Corp signs a definitive master services agreement with Genesis BioPharma Group and ABX-CRO Advanced Pharmaceutical Services to begin clinical studies and regulatory filings for its lead compound for the treatment of Alzheimer#s.
- Anavex comments on new Alzheimer’s disease diagnostic guidelines
Sources News Release
Resource Type: Article/Report/Letter
Published: 2011
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimer’s disease published recently by the National Institute on Aging (NIA) and the Alzheimer’s Association, which have been updated
- Anavex comments on President Obama’s signing of National Alzheimer’s Project Act into law
Sources News Release
Resource Type: Article/Report/Letter
Published: 2011
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today commented on President Obama’s signing of the National Alzheimer’s Project Act (NAPA) into law. The passage of this landmark legislation lays the foundation for the first coordinated national
- Anavex files Phase I regulatory submission for ANAVEX 2-73 in Alzheimer’s disease
Sources News Release
Resource Type: Article/Report/Letter
Published: 2011
Anavex Life Sciences Corp. has filed regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer
- Anavex presents data on neuroprotective evidence for ANAVEX 2-73, lead compound for Alzheimer’s disease
Sources News Release
Resource Type: Article/Report/Letter
Published: 2011
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “Preclinical development of new tetrahydrofur
- Anavex presents data on potential dual utility of ANAVEX 2-73 in both amyloid and tau pathology
Sources News Release
Resource Type: Article/Report/Letter
Published: 2011
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of the first of two poster presentations at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “The novel aminotetrahydrofuran deriva
- Anavex raises $1.575 million
Sources News Release
Resource Type: Article/Report/Letter
Published: 2011
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that it has raised US$1,575,000.00 through the exercise of warrants. Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73 the company’s lead drug candidate
- Anavex rapidly advances ANAVEX 2-73 for Alzheimer’s disease, Phase I clinical trial progressing well
Sources News Release
Resource Type: Article/Report/Letter
Published: 2011
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) has commenced the 30 mg dose step in its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease. This is the third of six potential dose
- Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease
Sources News Release
Resource Type: Article/Report/Letter
Published: 2011
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The
- Anavex Screening Healthy Volunteers For Phase I, First-In-Human Clinical Study in Alzheimer’s Disease
Sources News Release
Resource Type: Article/Report/Letter
Published: 2011
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is the first of a new
- Anavex to present at Alzheimer’s Association International Conference on Alzheimer’s Disease
Sources News Release
Resource Type: Article/Report/Letter
Published: 2011
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease (AD) currently in Phase I clinical trials, will be presented in two poster sessions at the 2011 Alzh
- Anavex to present at Rodman & Renshaw Healthcare Conference September 13 in New York
Sources News Release
Resource Type: Article/Report/Letter
Published: 2010
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that Dr. Cameron Durrant, the company#s Executive Chairman, will be presenting at the Rodman & Renshaw 12th Annual Healthcare Conference at 4:45 pm ET on Monday, September 13
- Anavex: First-In-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer’s Disease
Sources News Release
Resource Type: Article/Report/Letter
Published: 2011
Anavex Life Sciences Corp. (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease.
- Sources welcomes Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert
Sources News Release
Resource Type: Article/Report/Letter
Published: 2010
Sources welcomes a new member: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert.
|
AlterLinks
© Sources 2011. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.
|
